JPH10231292A - ２−アリール−３−アミノアリールオキシナフチル化合物、中間体、組成物及び方法 - Google Patents

２−アリール−３−アミノアリールオキシナフチル化合物、中間体、組成物及び方法

Info

Publication number
JPH10231292A
JPH10231292A JP9278908A JP27890897A JPH10231292A JP H10231292 A JPH10231292 A JP H10231292A JP 9278908 A JP9278908 A JP 9278908A JP 27890897 A JP27890897 A JP 27890897A JP H10231292 A JPH10231292 A JP H10231292A
Authority
JP
Japan
Prior art keywords
phenoxy
piperidinyl
hydroxyphenyl
estrogen
hydroxynaphthalene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP9278908A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10231292A5 (enExample
Inventor
Kenneth Lee Hauser
ケネス・リー・ハウザー
Alan David Palkowitz
アラン・デイビッド・パルコウィッツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH10231292A publication Critical patent/JPH10231292A/ja
Publication of JPH10231292A5 publication Critical patent/JPH10231292A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP9278908A 1996-10-10 1997-10-13 ２−アリール−３−アミノアリールオキシナフチル化合物、中間体、組成物及び方法 Withdrawn JPH10231292A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2844196P 1996-10-10 1996-10-10
US60/028441 1996-10-10

Publications (2)

Publication Number Publication Date
JPH10231292A true JPH10231292A (ja) 1998-09-02
JPH10231292A5 JPH10231292A5 (enExample) 2005-06-16

Family

ID=21843469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9278908A Withdrawn JPH10231292A (ja) 1996-10-10 1997-10-13 ２−アリール−３−アミノアリールオキシナフチル化合物、中間体、組成物及び方法

Country Status (8)

Country Link
EP (1) EP0835868B1 (enExample)
JP (1) JPH10231292A (enExample)
AT (1) ATE204868T1 (enExample)
CA (1) CA2217810A1 (enExample)
DE (1) DE69706386T2 (enExample)
DK (1) DK0835868T3 (enExample)
ES (1) ES2161417T3 (enExample)
PT (1) PT835868E (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538089A (ja) * 2002-07-22 2005-12-15 イーライ・リリー・アンド・カンパニー フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
JP2007519721A (ja) * 2004-01-22 2007-07-19 イーライ リリー アンド カンパニー 血管運動性症候の治療のための選択的エストロゲン受容体モジュレーター
JP2007537991A (ja) * 2003-02-25 2007-12-27 イーライ リリー アンド カンパニー 溶媒和していない結晶性１−（４−（２−ピペリジニルエトキシ）フェノキシ）−２−（４−メタンスルホニルフェニル）−６−ヒドロキシナフタレン塩酸塩
JP2008503588A (ja) * 2004-06-22 2008-02-07 スミスクライン ビーチャム コーポレーション 化学化合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID19392A (id) 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
EP1142862A3 (en) * 1996-08-29 2002-10-02 Eli Lilly And Company Naphthyl and tetralone derivatives as intermediates
CA2287244A1 (en) * 1997-04-25 1998-11-05 Henry Uhlman Bryant Indene compounds having activity as serms
WO2000041699A1 (en) * 1999-01-18 2000-07-20 Novo Nordisk A/S Use of estrogens and delta-gonadien-21-ol-3,20-diones
CA2379945A1 (en) * 1999-08-03 2001-02-08 Pharmacia Ab Liquid delivery container
WO2001026651A2 (en) * 1999-10-14 2001-04-19 Endorecherche, Inc. Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
SK622004A3 (en) * 2001-07-31 2004-08-03 Pfizer Prod Inc Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
CN1910167B (zh) * 2004-01-22 2011-08-10 伊莱利利公司 用于治疗血管舒缩症状的选择性雌激素受体调节剂
FR2913017A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
CN114133336B (zh) * 2020-09-03 2024-04-02 沈阳药科大学 4-甲氧基萘取代的苯胺类化合物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538089A (ja) * 2002-07-22 2005-12-15 イーライ・リリー・アンド・カンパニー フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
JP2010195820A (ja) * 2002-07-22 2010-09-09 Eli Lilly & Co フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
JP2007537991A (ja) * 2003-02-25 2007-12-27 イーライ リリー アンド カンパニー 溶媒和していない結晶性１−（４−（２−ピペリジニルエトキシ）フェノキシ）−２−（４−メタンスルホニルフェニル）−６−ヒドロキシナフタレン塩酸塩
JP2007519721A (ja) * 2004-01-22 2007-07-19 イーライ リリー アンド カンパニー 血管運動性症候の治療のための選択的エストロゲン受容体モジュレーター
JP2008503588A (ja) * 2004-06-22 2008-02-07 スミスクライン ビーチャム コーポレーション 化学化合物

Also Published As

Publication number Publication date
DE69706386D1 (de) 2001-10-04
ATE204868T1 (de) 2001-09-15
EP0835868A1 (en) 1998-04-15
ES2161417T3 (es) 2001-12-01
EP0835868B1 (en) 2001-08-29
DK0835868T3 (da) 2001-10-08
PT835868E (pt) 2001-12-28
CA2217810A1 (en) 1998-04-10
DE69706386T2 (de) 2002-05-23

Similar Documents

Publication Publication Date Title
US5916916A (en) 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US6437137B1 (en) Naphthyl compounds, intermediates, processes, compositions, and methods
US5510498A (en) Benzothiophene compounds, intermediates, compositions, and methods
JP3989569B2 (ja) ベンゾチオフェン化合物、中間体、組成物および方法
JPH08268881A (ja) ナフチル化合物、その中間体、該ナフチル化合物を含有する医薬組成物
JPH10231292A (ja) ２−アリール−３−アミノアリールオキシナフチル化合物、中間体、組成物及び方法
US5811421A (en) Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
EP0895989B1 (en) 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity
US5952350A (en) Naphthyl compounds and compositions, as estrogen receptor binding agents
US5929090A (en) 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
US5750708A (en) Pyridine compounds intermediates processes compositions and methods
US5856340A (en) Method of treating estrogen dependent cancers
EP0873992B1 (en) Indene compounds having activity as SERMs
US5958917A (en) Benzofluorene compounds, intermediates, compositions, and methods
JP2004531562A (ja) ２−置換１，２，３，４−テトラヒドロキノリンおよびその誘導体、組成物ならびに方法
US6962928B2 (en) Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
JPH11510163A (ja) ピリジン化合物、中間体、製法、組成物及び方法
CZ290200B6 (cs) Benzothiofenová sloučenina, meziprodukty pro její výrobu a farmaceutické prostředky tuto sloučeninu obsahující
JPH10147583A (ja) ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法
CZ9903552A3 (cs) Léčení poruch centrální nervové soustavy selektivními modulátory receptorů estrogenů

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040910

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20050822